Core Insights - The report highlights significant changes in the Hong Kong Stock Connect holdings, with notable increases and decreases in ownership percentages for various companies [1][2][3] Group 1: Companies with Increased Holdings - Haotian International Construction (01341) saw the largest increase in holdings, up by 5.66% to a total of 58.15% [2] - Hang Seng China Enterprises (02828) experienced a 5.47% increase, bringing its holding to 6.12% [2] - The Yingfu Fund (02800) increased by 4.10%, resulting in a holding of 4.75% [2] - Meizhong Jiahe (02453) had a notable increase of 9.06% over five days, reaching a holding of 34.31% [3] - Shandong Molong (00568) increased by 5.40% to 59.14% [3] - Changfei Optical Fiber (06869) saw a 5.35% increase, with a holding of 49.42% [3] Group 2: Companies with Decreased Holdings - Yisou Technology (02550) experienced the largest decrease, down by 8.45% to 48.02% [2] - Longpan Technology (02465) decreased by 1.67%, resulting in a holding of 46.71% [2] - Shandong Xinhua Pharmaceutical (00719) saw a reduction of 1.05%, bringing its holding to 41.70% [2] - Over the last five days, Yisou Technology (02550) had a significant drop of 9.99% to 48.02% [3] - Shandong Xinhua Pharmaceutical (00719) also decreased by 2.95% to 41.70% [3] - Chongqing Steel (01053) saw a reduction of 2.65%, with a holding of 34.17% [3] Group 3: Long-term Trends - Over the past 20 days, Haotian International Construction (01341) had a substantial increase of 25.58%, reaching a holding of 58.15% [4] - Changfei Optical Fiber (06869) increased by 21.92% to 49.42% [4] - Dongfang Electric (01072) saw a 13.44% increase, with a holding of 40.54% [4]

Core Viewpoint - Xinhua Pharmaceutical's stock price decreased by 1.71% to 16.69 yuan, with a trading volume of 190,900 hands and a transaction amount of 321 million yuan [1] Company Overview - Xinhua Pharmaceutical is primarily engaged in the research, production, and sales of chemical raw materials, formulations, and pharmaceutical intermediates, covering various therapeutic areas including antipyretic and analgesic, cardiovascular, anti-infection, and nervous system [1] Recent Developments - On August 5, the company announced that its wholly-owned subsidiary, Xinda Pharmaceutical, received approval from the National Medical Products Administration for the registration certificate of Finasteride tablets, which are used to treat benign prostatic hyperplasia and are classified as a Category B drug under medical insurance [1] - Public data indicates that the sales revenue of this drug in Chinese public medical institutions is expected to be approximately 1.45 billion yuan in 2024 [1] Financial Flow - On the day of the stock price decline, the net outflow of main funds for Xinhua Pharmaceutical was 26.63 million yuan, with a cumulative net outflow of 90.37 million yuan over the past five days [1]

Core Insights - The report highlights significant changes in the shareholding ratios of various companies under the Hong Kong Stock Connect program, indicating shifts in investor sentiment and potential investment opportunities. Group 1: Increased Shareholding Ratios - The companies with the largest increases in shareholding ratios include: - Hang Seng China Enterprises (02828) with an increase of 4.29%, reaching a holding ratio of 19.02% [1][2] - Dongjiang Environmental (00895) with an increase of 2.08%, reaching a holding ratio of 42.98% [1][2] - Meizhong Jiahe (02453) with an increase of 2.02%, reaching a holding ratio of 32.46% [1][2] - Over the last five trading days, the top gainers in shareholding ratios were: - Hang Seng China Enterprises (02828) with an increase of 11.75% [5] - Changfei Optical Fiber (06869) with an increase of 7.15%, reaching a holding ratio of 45.78% [5] - Zhengzhou Bank (06196) with an increase of 3.95%, reaching a holding ratio of 51.58% [5] Group 2: Decreased Shareholding Ratios - The companies with the largest decreases in shareholding ratios include: - Shandong Molong (00568) with a decrease of 3.32%, holding 58.15% [3][4] - Kanglong Chemical (03759) with a decrease of 1.21%, holding 54.05% [3][4] - Green Leaf Pharmaceutical (02186) with a decrease of 1.09%, holding 39.33% [3][4] - Over the last five trading days, the top decliners in shareholding ratios were: - Shandong Xinhua Pharmaceutical (00719) with a decrease of 5.14%, holding 42.62% [6] - Guolian Minsheng (01456) with a decrease of 2.30%, holding 52.59% [6] - Dongfang Electric (01072) with a decrease of 2.06%, holding 40.71% [6] Group 3: Long-term Trends - Over the last 20 trading days, the companies with the largest increases in shareholding ratios included: - Hang Seng China Enterprises (02828) with an increase of 18.02%, holding 19.02% [8] - Changfei Optical Fiber (06869) with an increase of 17.40%, holding 45.78% [8] - Junda Co., Ltd. (02865) with an increase of 14.19%, holding 27.55% [8] - The companies with the largest decreases in shareholding ratios over the last 20 trading days included: - Shijiazhuang Octagon (09676) with a decrease of 13.12%, holding 9.51% [9] - Marco Digital Technology (01942) with a decrease of 9.35%, holding 43.30% [9] - Tigermed (03347) with a decrease of 8.65%, holding 58.37% [9]

Core Viewpoint - Xinhua Pharmaceutical (000756) announced that its wholly-owned subsidiary, Shandong Zibo Xinda Pharmaceutical Co., Ltd., has received the drug registration certificate for Finasteride tablets from the National Medical Products Administration [1] Company Summary - Xinhua Pharmaceutical's subsidiary has successfully obtained regulatory approval for Finasteride tablets, indicating a significant milestone in expanding its product portfolio [1]

Core Insights - Xinhua Pharmaceutical's revenue composition for 2024 is as follows: 48.1% from chemical drug formulation manufacturing, 32.32% from chemical raw material manufacturing, and 19.59% from pharmaceutical intermediates and others [1]. Group 1 - Xinhua Pharmaceutical announced the approval of Finasteride tablets by the National Medical Products Administration [3]. - The product name for the newly approved drug is "Finasteride Tablets" [3].

Core Viewpoint - Xinhua Pharmaceutical (000756.SZ) has received approval from the National Medical Products Administration for the registration certificate of Finasteride tablets, which are indicated for the treatment and management of benign prostatic hyperplasia (BPH) [1] Group 1 - The approved Finasteride tablets are designed to treat and control BPH and to prevent urinary system events, including reducing the risk of acute urinary retention [1] - The medication can help shrink enlarged prostates, improve urinary flow, and alleviate symptoms associated with prostatic hyperplasia [1]

山东新华制药股份有限公司 关于子公司获得非那雄胺片药品注册证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导 性陈述或重大遗漏。 证券代码：000756 证券简称：新华制药 公告编号：2025-45 药品批准文号：国药准字H20255064 近日，山东新华制药股份有限公司之全资子公司山东淄博新达制药有限公司（以下简称 "新达制药"）收到国家药品监督管理局核准签发的非那雄胺片（以下简称"本品"）《药品 注册证书》。现将相关情况公告如下： 一、基本情况 药品名称：非那雄胺片 剂型：片剂 规格：5mg 药品分类：处方药 注册分类：化学药品4类 申请人：山东淄博新达制药有限公司 申请事项：境内生产药品注册上市许可 受理号：CYHS2400153 通知书编号：2025S02419 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品符合药品注 册的有关要求，批准注册，发给药品注册证书。质量标准、说明书、标签及生产工艺照所附 执行。药品生产企业应当符合药品生产质量管理规范要求方可生产销售。 二、其他相关信息 2024年1月，新达制药向国家药品监督管理局CDE递交非那雄胺 ...

Core Viewpoint - Xinhua Pharmaceutical (000756.SZ) has received approval from the National Medical Products Administration for the registration of Finasteride tablets, which are indicated for the treatment and management of benign prostatic hyperplasia (BPH) [1] Group 1: Product Information - Finasteride tablets are used to treat and control benign prostatic hyperplasia (BPH) and to prevent urinary system events [1] - The medication reduces the risk of acute urinary retention and the need for transurethral resection of the prostate (TURP) and prostatectomy [1] - Finasteride tablets can shrink enlarged prostates, improve urinary flow, and alleviate symptoms associated with prostatic hyperplasia [1]

Core Viewpoint - Xinhua Pharmaceutical (000756.SZ) has received approval from the National Medical Products Administration for the registration of Finasteride tablets, which are indicated for the treatment and management of benign prostatic hyperplasia (BPH) [1] Company Summary - The company's wholly-owned subsidiary, Shandong Zibo Xinda Pharmaceutical Co., Ltd., is responsible for the newly approved Finasteride tablets [1] - Finasteride tablets are designed to reduce the risk of acute urinary retention and the need for surgical procedures such as transurethral resection of the prostate (TURP) and prostatectomy [1] Industry Summary - Finasteride tablets can help shrink enlarged prostates, improve urinary flow, and alleviate symptoms associated with benign prostatic hyperplasia [1]

Core Viewpoint - Shandong Xinhua Pharmaceutical Co., Ltd. announced that its wholly-owned subsidiary, Shandong Zibo Xinda Pharmaceutical Co., Ltd., has received the drug registration certificate for Finasteride tablets from the National Medical Products Administration, which is expected to enhance the company's product portfolio and explore new market opportunities [1] Group 1 - The drug registration certificate for Finasteride tablets was obtained on August 2025 [1] - The approval is seen as beneficial for the company to diversify its product range [1] - The move is aimed at expanding into new market sectors [1]